Cell Therapy
NT-501 ECT Implant for Glaucoma
This trial tests a new eye implant called NT-501 for people with glaucoma. The implant releases medicine directly into the eye to help protect it from damage. It aims to help those who may not respond well to usual treatments. An earlier version of this implant has been used to help manage glaucoma in patients who did not benefit from other treatments.
Hormone Therapy
Topical Insulin for Glaucoma
This trial is testing the safety of applying a special form of insulin directly to the eye in patients with optic nerve damage from conditions like glaucoma. The insulin may help heal and protect the damaged nerve cells. Insulin eyedrops have been shown to be feasible for lowering blood glucose in humans and have been tested for safety and efficacy in animal models.
Popular Filters
Trials for Open-Angle Glaucoma Patients
Lumify for Glaucoma Side Effects
This trial is testing Lumify™ eye drops, which help reduce eye redness, in glaucoma patients who are already using Brimonidine eye drops. These patients often have red eyes as a side effect of their current treatment. Lumify™ works by making the blood vessels in the eyes smaller, which helps to reduce redness.
Device
Electrical Stimulation for Glaucoma
This trial is testing if using a home device that sends small electrical pulses to the eye can help treat open-angle glaucoma. It focuses on patients who are safe for this treatment but don't fit other trial criteria. The electrical pulses might help protect the eye nerves.
Trials for OAG Patients
Lumify for Glaucoma Side Effects
This trial is testing Lumify™ eye drops, which help reduce eye redness, in glaucoma patients who are already using Brimonidine eye drops. These patients often have red eyes as a side effect of their current treatment. Lumify™ works by making the blood vessels in the eyes smaller, which helps to reduce redness.
Device
Electrical Stimulation for Glaucoma
This trial is testing if using a home device that sends small electrical pulses to the eye can help treat open-angle glaucoma. It focuses on patients who are safe for this treatment but don't fit other trial criteria. The electrical pulses might help protect the eye nerves.
Phase 3 Trials
Laser Therapy
Selective Laser Trabeculoplasty for Glaucoma
This trial is testing if a lower-energy version of a common glaucoma treatment is as effective as the standard treatment, and if repeating the lower-energy treatment yearly is better than waiting for the treatment to wear off.
Prostaglandin Analog
NCX 470 for Glaucoma
This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
Prostaglandin Analog
Bimatoprost SR for Glaucoma
This trial tests a long-lasting eye medication called Bimatoprost SR. It is for people with certain eye conditions who can't use regular eye drops effectively. The medication works by helping fluid drain from the eye, reducing pressure. Bimatoprost has been widely used for glaucoma management, typically delivered via eye drops, but newer methods like sustained-release implants are being explored to improve efficiency.
Trials With No Placebo
Laser Treatment for Glaucoma Prevention in Corneal Disease
This trial is studying whether a laser treatment can help prevent glaucoma in patients receiving a Boston keratoprosthesis, a device used to restore vision in patients who have failed traditional corneal transplants.
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Procedure
GDD Timing with Boston KPro for Glaucoma
This trial will help surgeons to determine whether it is better to implant a glaucoma drainage device (GDD) at the time of the Boston KPro surgery or 6 months later, in the prevention of the progression of glaucoma.
View More Related Trials
Frequently Asked Questions
Introduction to glaucoma
What are the top hospitals conducting glaucoma research?
When it comes to advancing the field of ophthalmology and finding new treatments for glaucoma, several leading hospitals are making great strides. In Newport Beach, California, the Eye Research Foundation is dedicated to conducting research on this sight-threatening condition. With four active glaucoma trials currently underway and a total of 17 completed trials in their history, this foundation has been at the forefront of glaucoma research since their first recorded trial in 2007.
Similarly committed to advancing knowledge about glaucoma is Coastal Research Associates, LLC in Roswell, Georgia. This institution also boasts four ongoing clinical trials focused on finding innovative solutions for patients with glaucoma. Since initiating their first trial in 2010, they have conducted a commendable total of 16 studies dedicated to this eye disease.
Moving across the country to Boston's Massachusetts Eye and Ear hospital reveals another hub for groundbreaking research on glaucoma. Although relatively newer compared to other institutions listed here with only three ongoing clinical trials and three completed ones thus far as they began researching just last year in2021; however,the expertise housed within its walls promises significant contributions towards understanding this complex condition.
In Durham's Duke Eye Center too endeavors around similar lines can be witnessed where current investigations count up-to-three simultaneously being held while having previously carried out twelve such experiments starting from back whenit recordedits veryfirst examinationinthe yeartwo thousand thirteen.Across America at Stanford University's Byers Eye Institute located within Palo Alto emerges three active clinical tests concerningglaucomawhile counting five former examinationsfrom twothousand sixteen onwards.Most impressively- these figures prove that even smaller-scale projects are capable of driving impactful progress in tacklingthis silent thiefof vision.
These hospitals represent beacons of hope for those affected by glaucoma – a disease that silently steals sight if left untreated or undertreated.The dedication demonstratedby these prestigious medical establishmentsreiteratesthe importance of clinical trials in findingmore effective treatments,improving patient outcomes,and ultimately ensuring a brighter future for millions affected by this condition.
Which are the best cities for glaucoma clinical trials?
When it comes to glaucoma clinical trials, several cities have emerged as leaders in research and development. Among them are New york, San Antonio, Newport Beach, Boston, and Philadelphia. These cities collectively host a significant number of active trials focused on studying various treatments for glaucoma. From Rho-Kinase Inhibitors to Nicotinamide and Pyruvate interventions, Bimatoprost SR to ELIOS Procedures, AGN-193408 SR to Low Energy SLT techniques—these trials explore innovative approaches that hold promise for improving the management and treatment of glaucoma. With multiple ongoing studies in each city, individuals with glaucoma can find opportunities to participate in cutting-edge clinical trials that could potentially revolutionize glaucoma care.
Which are the top treatments for glaucoma being explored in clinical trials?
Glaucoma research is at the forefront of medical innovation, with several exciting treatments currently under exploration in clinical trials. Leading the charge is the Rho-Kinase Inhibitor, which has shown great promise in two active glaucoma trials since its initial listing in 2014. Another notable contender is sulcus tube placement, a novel treatment option that has already garnered interest with one ongoing trial and first listed just this year in 2023. As researchers delve deeper into these cutting-edge therapies, they bring us closer to revolutionizing glaucoma care and improving outcomes for patients worldwide.
What are the most recent clinical trials for glaucoma?
Exciting advancements are being made in the realm of glaucoma treatment, with several recent clinical trials offering promising prospects. One notable trial involves H-1337 0.6% Ophthalmic Solution administered twice daily for individuals with glaucoma. Another study focuses on Phase 1 Cohort B, which explores potential treatments through a combination of Phase 1 and Phase 2 testing. Additionally, researchers are investigating the effectiveness of a Latanoprost contact lens and topical insulin as potential therapies for glaucoma patients. Lastly, a trial involving Nicotinamide and Pyruvate is underway to evaluate their efficacy in treating this condition across Phases 2 and 3. These ongoing studies provide hope that improved management options for glaucoma may soon be within reach.
What glaucoma clinical trials were recently completed?
Several recently completed clinical trials have contributed to the advancement of glaucoma research. In October 2021, Qlaris Bio, Inc. successfully concluded trials for both QLS-101 ophthalmic solution 2% and Test - Bimatoprost 0.01% Ophthalmic Solution. The same month also saw the completion of a trial sponsored by Mankind Pharma Limited, testing TRS01 as a potential treatment option. Furthermore, Qlaris Bio, Inc.'s study on QLS-101 reached its conclusion in September 2021. These significant advancements hold promise for enhancing our understanding and management of glaucoma while offering hope to those affected by this debilitating condition.